Rigosertib: Difference between revisions
Content deleted Content added
Citation bot (talk | contribs) m Add: doi, year, pmc. | You can use this bot yourself. Report bugs here. | User-activated. |
m added reference |
||
| Line 29: | Line 29: | ||
}} |
}} |
||
'''Rigosertib''' ('''ON-01910''' sodium salt, with '''Estybon''' as trade name) is a synthetic benzyl styryl sulfone in development by [[Onconova Therapeutics]]. Riosertib is in [[phase III clinical trial]]s for the treatment of [[chronic myelomonocytic leukemia]].<ref>https://clinicaltrials.gov/ct2/show/NCT01928537</ref> |
'''Rigosertib''' ('''ON-01910''' sodium salt, with '''Estybon''' as trade name) is a synthetic benzyl styryl sulfone in development by [[Onconova Therapeutics]].<ref>{{Cite web|url=http://finpedia.co/bin/Companies/Onconova%20Therapeutics/|title=Onconova Therapeutics|access-date=2019-04-26}}</ref> Riosertib is in [[phase III clinical trial]]s for the treatment of [[chronic myelomonocytic leukemia]].<ref>https://clinicaltrials.gov/ct2/show/NCT01928537</ref> |
||
Its [[geometrical isomer]] (''Z'')-ON 01910·Na has less cytotoxicity on cancer cells. |
Its [[geometrical isomer]] (''Z'')-ON 01910·Na has less cytotoxicity on cancer cells. |
||
Revision as of 01:51, 27 April 2019
| |
| Names | |
|---|---|
| IUPAC name
2‐[(2‐Methoxy‐5‐{[(E)‐2‐(2,4,6‐trimethoxyphenyl)ethenesulfonyl]methyl}phenyl)amino]acetic acid
| |
| Other names
ON-01910
| |
| Identifiers | |
3D model (JSmol)
|
|
| ChEMBL | |
| ChemSpider | |
| KEGG | |
PubChem CID
|
|
CompTox Dashboard (EPA)
|
|
| Properties | |
| C21H25NO8S | |
| Molar mass | 451.49 g·mol−1 |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
| |
Rigosertib (ON-01910 sodium salt, with Estybon as trade name) is a synthetic benzyl styryl sulfone in development by Onconova Therapeutics.[2] Riosertib is in phase III clinical trials for the treatment of chronic myelomonocytic leukemia.[3]
Its geometrical isomer (Z)-ON 01910·Na has less cytotoxicity on cancer cells.
Mechanism
Rigosertib is a microtubule-destabilizing agent.[4]
References
- ^ "physical and chemical data on chemispider website".
- ^ "Onconova Therapeutics". Retrieved 2019-04-26.
- ^ https://clinicaltrials.gov/ct2/show/NCT01928537
- ^ Jost, M (2017). "Combined CRISPRi/a-Based Chemical Genetic Screens Reveal that Rigosertib Is a Microtubule-Destabilizing Agent". Molecular Cell. 68 (1): 210–223.e6. doi:10.1016/j.molcel.2017.09.012. PMC 5640507. PMID 28985505. Retrieved 29 May 2018.
 | This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |